The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project aims to determine molecular changes that drive childhood cancers, including osteosarcoma. The main purpose of the program is to use the open-source database to develop novel, effective, and less toxic therapies. We downloaded TARGET-OS RNA-Sequencing data through R studio and merged the mRNA expression of genes with clinical information (vital status, survival time and gender). Further, we analyzed differential gene expressions between dead and alive patients based on TARGET-OS project. By this study, we found 5758 differentially expressed genes between deceased and alive patients with a false discovery rate below 0.05; 4469 genes were upregulated in deceased patients compared to alive, whereas 1289 genes were downregulated. The survival-related genes were obtained using Kaplan–Meier survival analysis and Cox univariate regression (KM < 0.05 and Cox P-value < 0.05). Out of 5758 differentially expressed genes, only 217 have been associated with overall survival. Eight survival-related downregulated genes (ERCC4, CLUAP1, CTNNBIP1, GCA, RAB40C, SIRPA, USP11, and TCN2) and four survival-related upregulated genes (MUC1, COL13A1, JAG2 and KAZALD1) were selected for further analysis as potential independent prognostic candidate genes. This study may help to discover novel prognostic markers and potential therapeutic targets for osteosarcoma.
MirabelloLTroisiRJSavageSA.Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer2009;
115:1531–43
BermanSDCaloELandmanASDanielianPSMillerESWestJCFonhoueBDCaronABronsonRBouxseinMLMukherjeeSLeesJA.Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A2008;
105:11851–6
5.
BouvierCMacagnoNNguyenQLoundouAJiguet-JiglaireCGentetJCJouveJLRochwergerAMatteiJCBouvardDSalasS.Prognostic value of the hippo pathway transcriptional coactivators Yap/TAZ and beta1-integrin in conventional osteosarcoma. Oncotarget2016;
7:64702–10
6.
LamplotJDDenduluriSQinJLiRLiuXZhangHChenXWangNPrattAShuiWLuoXNanGDengZLLuoJHaydonRCHeTCLuuHH.The current and future therapies for human osteosarcoma. CCTR2013;
9:55–77
7.
PengHChenLZhangYLiWFMaoYPLiuXZhangFGuoRLiuLZTianLLinAHSunYMaJ.The tumour response to induction chemotherapy has prognostic value for Long-Term survival outcomes after Intensity-Modulated radiation therapy in nasopharyngeal carcinoma. Sci Rep2016;
6:24835
8.
DoneganWL.Tumor-related prognostic factors for breast cancer. CA Cancer J Clin1997;
47:28–51
WangZGersteinMSnyderM.RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet2009;
10:57–63
11.
KubeDMSavci-HeijinkCDLamblinAFKosariFVasmatzisGChevilleJCConnellyDPKleeGG.Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol2007;
8:25
12.
Milanez-AlmeidaPMartinsAJGermainRNTsangJS.Cancer prognosis with shallow tumor RNA sequencing. Nat Med2020;
26:188–92
13.
RobinsonMDMcCarthyDJSmythGK.edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics2010;
26:139–40
14.
McCarthyDJChenYSmythGK.Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res2012;
40:4288–97
15.
BenjaminiYH.Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc1995;
57:289–300
16.
GoldmanMJCraftBHastieMRepeckaKMcDadeFKamathABanerjeeALuoYRogersDBrooksANZhuJHausslerD.Visualizing and interpreting cancer genomics data via the xena platform. Nat Biotechnol2020;
38:675–8
17.
TulipanoPKMillarWSCiminoJJ.Linking molecular imaging terminology to the gene ontology (GO). Pac Symp Biocomput2003;613–23. DOI:10.1142/9789812776303_0057s
HuangRGrishaginIWangYZhaoTGreeneJObenauerJCNganDNguyenDTGuhaRJadhavASouthallNSimeonovAAustinCP.The NCATS BioPlanet - an integrated platform for exploring the universe of cellular signaling pathways for toxicology. Front Pharmacol2019;
10:445
DiaoCXiYXiaoT.Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol Lett2018;
15:2789–94
22.
IshikuraHIkedaHAbeHOhkuriTHiragaHIsuKTsukaharaTSatoNKitamuraHIwasakiNTakedaNMinamiANishimuraT.Identification of CLUAP1 as a human osteosarcoma tumor-associated antigen recognized by the humoral immune system. Int J Oncol2007;
30:461–7
23.
FanelliMTavantiEPatrizioMPVellaSFernandez-RamosAMagagnoliFLuppiSHattingerCMSerraM.Cisplatin resistance in osteosarcoma: in vitro validation of candidate DNA Repair-Related therapeutic targets and drugs for tailored treatments. Front Oncol2020;
10:331
24.
LiCYuXGuoDLiuGZhangKTengQLinH.Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis. Onco Targets Ther2018;
11:3495–504
25.
RayMLeeYWHardieJMoutRYesilbagTGFarkasMERotelloVM.CRISPRed macrophages for cell-based cancer immunotherapy. Bioconjug Chem2018;
29:445–50
26.
JiangLTolaniBYehCCFanYRezaJAHorvaiAEXiaEKratzJRJablonsDMMannMJ.Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma. Cancer Manag Res2019;
11:8209–18
27.
ManandharMBoulwareKSWoodRD.The ERCC1 and ERCC4 (XPF) genes and gene products. Gene2015;
569:153–61
28.
BoglioloMSchusterBStoepkerCDerkuntBSuYRaamsATrujilloJPMinguillonJRamirezMJPujolRCasadoJABanosRRioPKniesKZunigaSBenitezJBuerenJAJaspersNGScharerODde WinterJPSchindlerDSurrallesJ.Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause fanconi anemia. Am J Hum Genet2013;
92:800–6
29.
LevinsonSVincentKA.Multifocal osteosarcoma in a patient with fanconi anemia. J Pediatr Hematol Oncol1997;
19:251–3
30.
YangLXuMCuiCBWeiPHWuSZCenZJMengXXHuangQGXieZC.Diagnostic and prognostic values of the mRNA expression of excision repair cross-complementation enzymes in hepatitis B virus-related hepatocellular carcinoma. Cancer Manag Res2018;
10:5313–28
31.
TakahashiMLinYMNakamuraYFurukawaY.Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer. Oncogene2004;
23:9289–94
32.
QiWChenJChengXHuangJXiangTLiQLongHZhuB.Targeting the Wnt-regulatory protein CTNNBIP1 by microRNA-214 enhances the stemness and self-renewal of cancer stem-like cells in lung adenocarcinomas. Stem Cells2015;
33:3423–36
33.
XuPRoesJSegalAWRadulovicM.The role of grancalcin in adhesion of neutrophils. Cell Immunol2006;
240:116–21
34.
LisleJWChoiJYHortonJAAllenMJDamronTA.Metastatic osteosarcoma gene expression differs in vitro and in vivo. Clin Orthop Relat Res2008;
466:2071–80
35.
NagaharaMMimoriKKataokaAIshiiHTanakaFNakagawaTSatoTOnoSSugiharaKMoriM.Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res2010;
16:4625–35
36.
LuoZWLiuPPWangZXChenCYXieH.Macrophages in osteosarcoma immune microenvironment: implications for immunotherapy. Front Oncol2020;
10:586580
37.
BayraktarSGutierrez BarreraAMLiuDPusztaiLLittonJValeroVHuntKHortobagyiGNWuYSymmansFArunB.USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J2013;
19:10–7
38.
SunHOuBZhaoSLiuXSongLLiuXWangRPengZ.USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway. EBioMedicine2019;
48:236–47
39.
ZhanSChengFHeHHuSFengX.Identification of transcobalamin deficiency with two novel mutations in the TCN2 gene in a Chinese girl with abnormal immunity: a case report. BMC Pediatr2020;
20:460
40.
HormTMSchroederJA.MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr2013;
7:187–98
41.
JingXLiangHHaoCYangXCuiX.Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep2019;
41:801–10
42.
MiyakeMMorizawaYHoriSTatsumiYOnishiSOwariTIidaKOnishiKGotohDNakaiYAnaiSChiharaYTorimotoKAokiKTanakaNShimadaKKonishiNFujimotoK.Diagnostic and prognostic role of urinary collagens in primary human bladder cancer. Cancer Sci2017;
108:2221–8
43.
MiyakeMHoriSMorizawaYTatsumiYToritsukaMOhnishiSShimadaKFuruyaHKhadkaVSDengYOhnishiKIidaKGotohDNakaiYInoueTAnaiSTorimotoKAokiKTanakaNKonishiNFujimotoK.Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. Oncotarget2017;
8:36099–114
44.
HatanoKSaigoCKitoYShibataTTakeuchiT.Overexpression of JAG2 is related to poor outcomes in oral squamous cell carcinoma. Clin Exp Dent Res2020;
6:174–80
45.
VaishVKimJShimM.Jagged-2 (JAG2) enhances tumorigenicity and chemoresistance of colorectal cancer cells. Oncotarget2017;
8:53262–75
46.
HartlM.The quest for targets executing MYC-dependent cell transformation. Front Oncol2016;
6:132
47.
FiaschettiGCastellettiDZollerSSchrammASchroederCNagaishiMStearnsDMittelbronnMEggertAWestermannFOhgakiHShalabyTPruschyMArcaroAGrotzerMA.Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene2011;
30:2823–35
48.
ParkHSKimCGHongNLeeSJSeoDHRheeY.Osteosarcoma in a patient with pseudohypoparathyroidism type 1b due to paternal uniparental disomy of chromosome 20q. J Bone Miner Res2017;
32:770–5
49.
SasakiYIshidaSMorimotoIYamashitaTKojimaTKiharaCTanakaTImaiKNakamuraYTokinoT.The p53 family member genes are involved in the notch signal pathway. J Biol Chem2002;
277:719–24
50.
WangHFengYBaoZJiangCYanWWangYZhangCLiuYZhangQZhangWJiangC.Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma. Oncol Rep2013;
30:2089–96
